Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
June 22, 2023 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis...
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 25, 2023 16:26 ET
|
Adamis Pharmaceuticals Corporation
DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical...
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 16:47 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in...
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
May 08, 2023 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023 16:24 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
March 14, 2023 16:01 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
March 14, 2023 08:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
February 27, 2023 16:05 ET
|
Adamis Pharmaceuticals Corporation
Combined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead...
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
February 22, 2023 16:01 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:10 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...